Matthew M. Bio
Amgen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew M. Bio.
Journal of the American Chemical Society | 2013
John R. Huckins; Eric A. Bercot; Oliver R. Thiel; Tsang-Lin Hwang; Matthew M. Bio
A general Rh(III)-catalyzed synthesis of naphthyridinone derivatives is described. It relies on a double-activation and directing approach leveraging nicotinamide N-oxides as substrates. In general, high yields and selectivities can be achieved using low catalyst loadings and mild conditions (room temperature) in the couplings with alkynes, while alkenes require slightly more elevated temperatures.
Journal of the American Chemical Society | 2010
Yuanqing Fang; Matthew M. Bio; Karl B. Hansen; Matthew S. Potter; Andrew M. Clausen
A general inversion-stereospecific, N-selective alkylation of substituted 2-pyridones (and analogues), amides, and carbamates using chiral α-chloro- or bromocarboxylic acids in the presence of KOt-Bu (or KHMDS) and Mg(Ot-Bu)(2) is reported. The resulting α-chiral carboxylic acid products were isolated by crystallization in good chemical yields and in high ee (>90% ee). Mechanistic evidence suggests that the reaction proceeds through 2-pyridone O-coordinated Mg carboxylate intermediates, which afford the product through an intramolecular S(N)2 alkylation.
Cancer Research | 2015
Kevin J. Hamblett; Allison P. Jacob; Jesse L. Gurgel; Mark E. Tometsko; Brooke M. Rock; Sonal Patel; Robert R. Milburn; Sophia Siu; Seamus Ragan; Dan A. Rock; Christopher J. Borths; Jason W. O'Neill; Wesley S. Chang; Margaret Weidner; Matthew M. Bio; William C. Fanslow
Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-positive cells for treating cancer. After internalization, ADCs with noncleavable linkers are catabolized to amino acid-linker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism. We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm. To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC. This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibody-maytansine ADCs, including ado-trastuzumab emtansine. In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation. Structure-activity experiments suggested that maytansine is a substrate for SLC46A3. Notably, SLC46A3 silencing led to relative increases in catabolite concentrations in the lysosome. Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens.
Organic Letters | 2015
Ying Chen; Jinkun Huang; Tsang-Lin Hwang; Maosheng J. Chen; Jason Tedrow; Robert P. Farrell; Matthew M. Bio; Sheng Cui
A highly efficient and regioselective halogenation reaction of unsymmetrical pyridine N-oxide under mild conditions is described. The methodology provides a practical access to various 2-halo-substituted pyridines, which are pharmaceutically important intermediates.
Journal of Organic Chemistry | 2011
Johann Chan; Brenda J. Burke; Kyle D. Baucom; Karl B. Hansen; Matthew M. Bio; Evan DiVirgilio; Margaret M. Faul; Jerry Murry
Two new, reliable syntheses of a pyrido[2,3-d]-pyrimidine inhibitor of the CXCR3 receptor are described. A nine-step synthesis of the CXCR3 inhibitor (1) from 2-aminonicotinic acid was demonstrated on a multikilogram scale and incorporates a classic resolution to deliver the enantioenriched active pharmaceutical ingredient (API). A second synthesis of the CXCR3 inhibitor starts from (+)-(D)-Boc alanine and 2-chloronicotinic acid and utilizes a Goldberg coupling. This second synthesis, performed on a gram scale, intersects the former route at a common intermediate thereby completing a formal synthesis of the enantioenriched API in higher overall yield without the need for a resolution.
Journal of Organic Chemistry | 2016
Michal Achmatowicz; John G. Allen; Matthew M. Bio; Michael D. Bartberger; Christopher J. Borths; John T. Colyer; Richard Crockett; Tsang-Lin Hwang; Jan. N. Koek; Stephen A. Osgood; Scott W. Roberts; Aleksander Swietlow; Oliver R. Thiel; Seb Caille
IgG1 monoclonal antibodies with reduced glycan fucosylation have been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allowing more effective binding of the Fc region of these proteins to T cells receptors. Increased in vivo efficacy in animal models and oncology clinical trials has been associated with the enhanced ADCC provided by these engineered mAbs. 6,6,6-Trifluorofucose (1) is a new inhibitor of fucosylation that has been demonstrated to allow the preparation of IgG1 monoclonal antibodies with lower fucosylation levels and thus improve the ADCC of these proteins. A new process has been developed to support the preparation of 1 on large-scale for wide mAb manufacture applications. The target fucosylation inhibitor (1) was synthesized from readily available d-arabinose in 11% overall yield and >99.5/0.5 dr (diastereomeric ratio). The heavily telescoped process includes seven steps, two crystallizations as purification handles, and no chromatography. The key transformation of the sequence involves the diastereoselective preparation of the desired trifluoromethyl-bearing alcohol in >9/1 dr from a trimethylsilylketal intermediate via a ruthenium-catalyzed tandem ketal hydrolysis-transfer hydrogenation process.
Organic Letters | 2018
Hui Li; Christopher P. Breen; Hyowon Seo; Timothy F. Jamison; Yuanqing Fang; Matthew M. Bio
An electrochemically driven, nickel-catalyzed reductive coupling of N-hydroxyphthalimide esters with aryl halides is reported. The reaction proceeds under mild conditions in a divided electrochemical cell and employs a tertiary amine as the reductant. This decarboxylative C(sp3)–C(sp2) bond-forming transformation exhibits excellent substrate generality and functional group compatibility. An operationally simple continuous-flow version of this transformation using a commercial electrochemical flow reactor represents a robust and scalable synthesis of value added coupling process.
Angewandte Chemie | 2017
Hui Li; Jillian W. Sheeran; Andrew M. Clausen; Yuanqing Fang; Matthew M. Bio; Scott Bader
The development of a flow chemistry process for asymmetric propargylation using allene gas as a reagent is reported. The connected continuous process of allene dissolution, lithiation, Li-Zn transmetallation, and asymmetric propargylation provides homopropargyl β-amino alcohol 1 with high regio- and diastereoselectivity in high yield. This flow process enables practical use of an unstable allenyllithium intermediate. The process uses the commercially available and recyclable (1S,2R)-N-pyrrolidinyl norephedrine as a ligand to promote the highly diastereoselective (32:1) propargylation. Judicious selection of mixers based on the chemistry requirement and real-time monitoring of the process using process analytical technology (PAT) enabled stable and scalable flow chemistry runs.
Journal of Organic Chemistry | 2004
Matthew M. Bio; Feng Xu; Marjorie S. Waters; J. Michael Williams; Kimberly A. Savary; Cameron J. Cowden; Chunhua Yang; Elizabeth Buck; Zhiguo J. Song; David M. Tschaen; Ralph P. Volante; Robert A. Reamer; Edward J. J. Grabowski
Journal of the American Chemical Society | 1999
Matthew M. Bio; James L. Leighton